222 related articles for article (PubMed ID: 33875671)
1. Blood tryptase and thymic stromal lymphopoietin levels predict the risk of exacerbation in severe asthma.
Ko HK; Cheng SL; Lin CH; Lin SH; Hsiao YH; Su KC; Yu CJ; Wang HC; Sheu CC; Chiu KC; Perng DW
Sci Rep; 2021 Apr; 11(1):8425. PubMed ID: 33875671
[TBL] [Abstract][Full Text] [Related]
2. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study.
Price DB; Rigazio A; Campbell JD; Bleecker ER; Corrigan CJ; Thomas M; Wenzel SE; Wilson AM; Small MB; Gopalan G; Ashton VL; Burden A; Hillyer EV; Kerkhof M; Pavord ID
Lancet Respir Med; 2015 Nov; 3(11):849-58. PubMed ID: 26493938
[TBL] [Abstract][Full Text] [Related]
3. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
4. Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatments.
Trevor J; Lugogo N; Carr W; Moore WC; Soong W; Panettieri RA; Desai P; Trudo F; Ambrose CS
Ann Allergy Asthma Immunol; 2021 Nov; 127(5):579-587.e1. PubMed ID: 34273485
[TBL] [Abstract][Full Text] [Related]
5. Sputum Type 2 Markers Could Predict Remission in Severe Asthma Treated With Anti-IL-5.
Moermans C; Brion C; Bock G; Graff S; Gerday S; Nekoee H; Poulet C; Bricmont N; Henket M; Paulus V; Guissard F; Louis R; Schleich F
Chest; 2023 Jun; 163(6):1368-1379. PubMed ID: 36740095
[TBL] [Abstract][Full Text] [Related]
6. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
Goldman M; Hirsch I; Zangrilli JG; Newbold P; Xu X
Curr Med Res Opin; 2017 Sep; 33(9):1605-1613. PubMed ID: 28644104
[TBL] [Abstract][Full Text] [Related]
7. Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes.
McDowell PJ; Busby J; Hanratty CE; Djukanovic R; Woodcock A; Walker S; Hardman TC; Arron JR; Choy DF; Bradding P; Brightling CE; Chaudhuri R; Cowan D; Mansur AH; Fowler SJ; Diver SE; Howarth P; Lordan J; Menzies-Gow A; Harrison T; Robinson DS; Holweg CTJ; Matthews JG; Pavord ID; Heaney LG
Am J Respir Crit Care Med; 2022 Sep; 206(5):545-553. PubMed ID: 35549845
[No Abstract] [Full Text] [Related]
8. Association between Serum Levels of Interleukin-25/Thymic Stromal Lymphopoietin and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease.
Choi JY; Kim TH; Kang SY; Park HJ; Lim SY; Kim SH; Jung KS; Yoo KH; Yoon HK; Rhee CK
Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979498
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum OX40L is a biomarker for identifying corticosteroid resistance in pediatric asthmatic patients.
Ma SL; Zhang L
BMC Pulm Med; 2019 Mar; 19(1):66. PubMed ID: 30890137
[TBL] [Abstract][Full Text] [Related]
10. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
11. Characteristics associated with clinical severity and inflammatory phenotype of naturally occurring virus-induced exacerbations of asthma in adults.
Bjerregaard A; Laing IA; Poulsen N; Backer V; Sverrild A; Fally M; Khoo SK; Barrett L; Baltic S; Thompson PJ; Chidlow G; Sikazwe C; Smith DW; Bochkov YA; Le Souëf P; Porsbjerg C
Respir Med; 2017 Feb; 123():34-41. PubMed ID: 28137494
[TBL] [Abstract][Full Text] [Related]
12. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Diver S; Khalfaoui L; Emson C; Wenzel SE; Menzies-Gow A; Wechsler ME; Johnston J; Molfino N; Parnes JR; Megally A; Colice G; Brightling CE;
Lancet Respir Med; 2021 Nov; 9(11):1299-1312. PubMed ID: 34256031
[TBL] [Abstract][Full Text] [Related]
13. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
[TBL] [Abstract][Full Text] [Related]
14. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults.
Petsky HL; Li A; Chang AB
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD005603. PubMed ID: 28837221
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
16. Thymic stromal lymphopoietin (TSLP) is a substrate for tryptase in patients with mastocytosis.
Marcella S; Petraroli A; Canè L; Ferrara AL; Poto R; Parente R; Palestra F; Cristinziano L; Modestino L; Galdiero MR; Monti M; Marone G; Triggiani M; Varricchi G; Loffredo S
Eur J Intern Med; 2023 Nov; 117():111-118. PubMed ID: 37500310
[TBL] [Abstract][Full Text] [Related]
17. Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma.
Türk M; Yılmaz İ; Gökahmetoğlu S; Koç AN
Turk J Med Sci; 2022 Aug; 52(4):1148-1159. PubMed ID: 36326393
[TBL] [Abstract][Full Text] [Related]
18. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
19. Tezepelumab in Adults with Uncontrolled Asthma.
Corren J; Parnes JR; Wang L; Mo M; Roseti SL; Griffiths JM; van der Merwe R
N Engl J Med; 2017 Sep; 377(10):936-946. PubMed ID: 28877011
[TBL] [Abstract][Full Text] [Related]
20. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma.
Zeiger RS; Schatz M; Li Q; Chen W; Khatry DB; Gossage D; Tran TN
J Allergy Clin Immunol Pract; 2014; 2(6):741-50. PubMed ID: 25439366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
